Predictors of disease activity score improvement in pediatric rheumatology patients with rheumatoid arthritis

Abstract

Background: Composite disease activity indices such as the juvenile arthritis disease activity score (JADAS) and its clinical variant now anchor treat-to-target management of pediatric rheumatoid arthritis, yet the pace and completeness of score improvement after treatment initiation vary widely between children.

Objective: This review synthesizes the published evidence on baseline and early-treatment predictors of disease activity score improvement in pediatric patients with polyarticular and oligoarticular rheumatoid arthritis (juvenile idiopathic arthritis).

Methods: We synthesized inception-cohort studies, randomized biologic and treat-to-target trials, national registries, and long-term outcome cohorts addressing disease activity score trajectory, response definitions, and their baseline predictors.

Findings: Rheumatoid-factor-positive polyarticular subtype, high baseline joint count and poor functional status, and longer delay between symptom onset and effective therapy each predict slower, less complete score improvement, while early achievement of inactive disease and management under a structured treat-to-target protocol predict a more favorable and more sustained trajectory; composite models combining these domains consistently outperform any single baseline variable.

Conclusions: Disease subtype and seropositivity, baseline disease burden, time to effective treatment, and adherence to score-driven treat-to-target escalation together explain much of the variation in disease activity score improvement among children with rheumatoid arthritis, and prospective validation of these predictors under contemporary treat-to-target protocols remains a priority for the field.